Literature DB >> 12082210

Polycystic ovary syndrome and fat distribution: the central issue?

Jonathan Lord1, Terence Wilkin.   

Abstract

This review discusses the role of central obesity in polycystic ovary syndrome. There is increasing evidence that intraabdominal or visceral fat is either causative or a very early effect of polycystic ovary syndrome. The clinical implications of this are discussed. The simplest technique for assessing visceral fat and monitoring treatment is to measure waist circumference rather than waist:hip ratio or body weight. Weight loss is an effective treatment even where there is only a very modest reduction. The key element in lifestyle modification is regular exercise.

Entities:  

Mesh:

Year:  2002        PMID: 12082210     DOI: 10.1080/1464727022000198952

Source DB:  PubMed          Journal:  Hum Fertil (Camb)        ISSN: 1464-7273            Impact factor:   2.767


  4 in total

Review 1.  Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.

Authors:  Lara C Morley; Thomas Tang; Ephia Yasmin; Robert J Norman; Adam H Balen
Journal:  Cochrane Database Syst Rev       Date:  2017-11-29

2.  Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease.

Authors:  Andrew J Krentz; Denise von Mühlen; Elizabeth Barrett-Connor
Journal:  Menopause       Date:  2007 Mar-Apr       Impact factor: 2.953

3.  Sleep and cardiometabolic function in obese adolescent girls with polycystic ovary syndrome.

Authors:  Kiran Nandalike; Chhavi Agarwal; Temima Strauss; Susan M Coupey; Carmen R Isasi; Sanghun Sin; Raanan Arens
Journal:  Sleep Med       Date:  2012-08-23       Impact factor: 3.492

4.  Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome.

Authors:  Abigail Sharpe; Lara C Morley; Thomas Tang; Robert J Norman; Adam H Balen
Journal:  Cochrane Database Syst Rev       Date:  2019-12-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.